The nation of Zimbabwe has turned down a substantial American health deal worth $367m (£272m) spanning five years because of Washington's demand for sensitive data.
This move came to light following a government memo from December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "skewed".
A government representative has since clarified that the US was seeking genetic material for scientific study and commercial purposes while was unwilling to share the benefits from future vaccines.
"We must now begin the challenging and unfortunate process of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged continued negotiations to reach a deal suitable to all parties so the country's critical HIV programme can be sustained.
Wider Context
This development follows a similar situation in Kenya, where a high court halted a similar deal with the US following legal challenges were filed about the safety of citizens' medical information.
After returning to office recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had managed aid for the US government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to enhance transparency and responsibility.
Based on statements, Sixteen nations in Africa have so far signed similar agreements, representing more than $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million presently on antiretroviral therapy via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information indefinitely, with no equivalent guarantee of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"Effectively, our nation would provide the raw materials for scientific discovery with no certainty that the final treatments would be available to our citizens if a future health crisis emerge."
National Interest and Global Health
He also said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral health agreements were undermining structures previously set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This system is intended to guarantee that when a nation contributes its data, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how future collaboration could be designed in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body stated it acknowledged the government's concerns, but urged that negotiations need to persist given that much of the nation's HIV programmes depended on international support.
"In cases where technical issues arise, such as those relating to information security or implementation frameworks, these can often be resolved through detailed discussion and mutually agreed protections," it said.
The situation emphasises the complex challenges between accepting crucial international aid and protecting local interests in an increasingly data-driven world.